InsiderDirector
Blake Borgeson Insider Trading Activity
Every SEC Form 4 transaction reported by Blake Borgeson, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Is Blake Borgeson buying or selling?
Blake Borgeson reported 0 open-market buys ($0) and 62 sells ($9.9M) across 62 Form 4 filings at 1 company — a net selling position of $9.9M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 9, 2026)
Total Form 4 filings
62
SEC EDGAR
Companies
1
Buys (0)
$0
Sells (62)
$9.9M
Insider sentiment
Net sellingNet insider flow of $9.9M in net selling, filed between Nov 23, 2021 – Jul 9, 2026.
Companies Blake Borgeson files for
| # | Company | Form 4 filings |
|---|---|---|
| 1 | RXRXRECURSION PHARMACEUTICALS, INC. | 62 |
Recent Blake Borgeson transactions
| Date | Ticker | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jul 9, 2026 | RXRX | Director | Sale | 40.0K | $158.5K |
| Jun 4, 2026 | RXRX | Director | Sale | 30.0K | $110.4K |
| May 7, 2026 | RXRX | Director | Sale | 30.0K | $105.6K |
| Apr 8, 2026 | RXRX | Director | Sale | 30.0K | $93.0K |
| Mar 4, 2026 | RXRX | Director | Sale | 170.0K | $588.2K |
| Feb 6, 2026 | RXRX | Director | Sale | 220.0K | $924.0K |
| Jan 8, 2026 | RXRX | Director | Sale | 220.0K | $959.2K |
| Dec 4, 2025 | RXRX | Director | Sale | 220.0K | $961.4K |
| Nov 15, 2024 | RXRX | Director | Sale | 11.4K | $87.5K |
| Oct 31, 2024 | RXRX | Director | Sale | 11.4K | $76.9K |
| Oct 17, 2024 | RXRX | Director | Sale | 11.4K | $76.3K |
| Oct 3, 2024 | RXRX | Director | Sale | 11.4K | $71.1K |
| Sep 19, 2024 | RXRX | Director | Sale | 11.4K | $78.3K |
| Sep 5, 2024 | RXRX | Director | Sale | 11.4K | $71.7K |
| Aug 22, 2024 | RXRX | Director | Sale | 11.4K | $81.5K |
| Aug 8, 2024 | RXRX | Director | Sale | 11.4K | $78.1K |
| Jul 25, 2024 | RXRX | Director | Sale | 11.4K | $97.0K |
| Jul 11, 2024 | RXRX | Director | Sale | 11.4K | $83.7K |
| Jun 27, 2024 | RXRX | Director | Sale | 11.4K | $108.8K |
| Jun 13, 2024 | RXRX | Director | Sale | 11.4K | $96.8K |
| May 30, 2024 | RXRX | Director | Sale | 11.4K | $104.9K |
| May 16, 2024 | RXRX | Director | Sale | 20.1K | $202.9K |
| May 2, 2024 | RXRX | Director | Sale | 11.4K | $91.0K |
| Apr 18, 2024 | RXRX | Director | Sale | 11.4K | $87.7K |
| Apr 3, 2024 | RXRX | Director | Sale | 11.4K | $100.9K |
Showing the 25 most recent filings of 62. Screen every filing.
Blake Borgeson insider trading FAQ
Is Blake Borgeson buying or selling?
Across 62 SEC Form 4 filings, Blake Borgeson reported 0 open-market purchases totaling $0 and 62 sales totaling $9.9M — a net selling position of $9.9M.
Which companies does Blake Borgeson file Form 4s for?
Blake Borgeson has reported insider transactions at 1 company, most often RECURSION PHARMACEUTICALS, INC. (RXRX).
How far back does Blake Borgeson's filing history go?
Trabud holds Blake Borgeson's SEC Form 4 filings from Nov 23, 2021 – Jul 9, 2026, sourced directly from SEC EDGAR.
Where does Trabud get Blake Borgeson's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track Blake Borgeson and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener